Although the high mortality of invasive pulmonary aspergillosis (IA) in patients with prolonged 27 chemotherapy-induced neutropenia (PCIN) can be reduced by timely diagnosis, a diagnostic test that 28 reliably detects IA at an early stage is lacking. We hypothesized that an electronic nose (eNose) can 29 fulfill this need. An eNose can discriminate various lung diseases through analysis of exhaled volatile 30 organic compounds (VOC's). An eNose is cheap, non-invasive and yields results within minutes. 31
Introduction 45 46
The diagnosis of invasive pulmonary aspergillosis poses a significant challenge in clinical practice, due 47
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Antifungal prophylaxis -All patients were managed identically and according to a standardized 115 protocol based on recent guidelines with respect to the prevention, diagnosis and treatment of 116 mycoses.(23) Except for analysis of exhaled air using the eNose every prophylactic, diagnostic and 117 treatment-related procedure was according to standard care. Prophylactic antifungal treatment was 118 started the same day as the chemotherapy. Patients received 500 mg amphotericine B every 6 hours 119 orally until the peripheral neutrophil count exceeded 0.5 x 10 9 /L. Patients undergoing myeloablative 120 allogeneic stem cell transplantation received 200 mg of fluconazole daily. If oral amphotericine B was 121 not tolerated, no substitute was started. In principle, no antimycotics with activity against Aspergillus 122
spp., such as voriconazole or posaconazole, were administered prophylactically. If the treating 123 physician judged that the administration of prophylactic anti-mold treatment was necessary, the patient 124 was excluded from the study as eNose results could be influenced by anti-mold therapy. 125 126 Diagnostic strategy -From the start of chemotherapy onwards cultures of throat, nose, rectum and, if 127 possible, sputum were performed weekly. From the start of neutropenia (<0.5 x 10 9 neutrophils/L) a 128 serum galactomannan assay was performed twice weekly. Both were continued until the peripheral 129 neutrophil count exceeded 0.5 x 10 9 /L. A complete diagnostic workup was performed in case of a 130 number of standardized indications for a diagnostic workup, based on international guidelines: 1) a rise 131 of serum galactomannan above 0.5, or 2) five or more days of fever unresponsive to broad empiric 132 antibiotic treatment and without alternative explanation, or 3) a new infiltrate developing under broad 133 antibiotic coverage or highly dosed steroids, or 4) an abnormality on a chest X-ray consistent with 134 invasive pulmonary mycosis, or 5) hyphae or molds found in a respiratory specimen, or 6) symptoms 135 and/or signs considered by the treating physician to be possibly due to an invasive mycosis. (23) 136 137 Diagnostic workup -The workup consisted of 1) analysis of sputum (using direct microscopy and7 / 19 culture), 2) a high resolution CT of the thorax, 3) in case of abnormalities on the HR-CT consistent 139 with invasive pulmonary mycosis bronchoscopy and broncho-alveolar lavage. The BAL was examined 140 using direct microscopy; a PCR on M.tuberculosis complex, mycobacterial culture, PCR's on 141 respiratory viruses (human boca virus, parainfluenza 1 to 4, parechovirus, coronavirus, rhinovirus, 142 RSV, human metapneumovirus, enterovirus, influenza A and B, adenovirus, HSV, EBV, CMV), routine 143 culture and measurement of galactomannan were performed as well. In case a broncho-alveolar lavage 144
was not performed a throat gurgle specimen was examined using PCR's on the abovementioned 145 respiratory viruses. Sinonasal, ophthalmological and neurological symptoms and signs were actively 146 sought. On indication CT of the liver and spleen, CT or MRI of the brain and sinus, consultation of a 147 neurologist, otolaryngologist or ophthalmologist was performed. 148
149
Exhaled breath analysis -Every "diagnostic workup" was followed by exhaled breath analysis as 150 previously described. (11, 24) Patients were asked to breath through a mouthpiece for 5 minutes with 151 the nose clipped. Through a three-way non-rebreathing valve this mouthpiece was connected to an 152 inspiratory VOC filter (A2; North Safety, Middelburg, The Netherlands) as well as an expiratory silica 153 reservoir. Then, a deep inspiratory capacity maneuver was followed by the exhalation of a vital 154 capacity volume. The exhaled breath was collected in a 10 liter Tedlar bag which was connected to the 155 silica reservoir. Within 30 minutes the Tedlar bag was sampled using the electronic nose, a Cyranose 156 320 ® (Smith Detections, Pasadena, CA). This is a hand-held chemical vapor analyzer based on a nano-157 composite sensor array with 32 polymer sensors. (19) The change in electrical resistance in each of the 158 32 sensors was stored as raw data for further analysis. Every sampling procedure was repeated after 159 which the first measurement was disregarded, as previously described because of deviant raw data at 160 first run. (11) 161 162 8 / 19
Analysis -As our primary analysis we compared the breathprints of cases and controls. We performed 163 offline analysis of the raw data using R (version 2.11.1). First, data reduction by principal component 164 analysis (PCA) was performed to reduce the original data of the 32 sensors to a non-predefined number 165 of principal components, capturing at least 99.9% of the variance within the dataset. Secondly, t-tests 166 (equal variance assumed depending on the outcome of an F-test) were used to assess which PCA 167 factors discriminated between the two groups; a two-sided p-value of 0.10 was considered significant. 168
Then, based on the differentiating PCA factors a categorical division was made using linear canonical 169 discriminant analysis, assuming an equal chance of being a member of one of the two groups. The 170 discriminant function was chosen to best distinguish between categories. Finally, the accuracy of this 171 model was established. This was defined as the percentage of correctly classified patients, cases and 172 control subjects combined. Cross-validation using the leave-one out method was used to calculate the 173 cross-validated accuracy. The 95% confidence intervals (CI) were calculated using the exact binomial 174 test. To calculate our p-value, we generated 100,000 random classifications of our subjects ("whether or 175 not case or control") and determined the chance that a random classification would have led to a cross-176 validated accuracy identical to our primary outcome or better, constructing a new pattern recognition 177 algorithm for each of the random classifications using the statistical method of the primary 178 analysis.(25) Finally, ROC analysis was performed.
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Results 180 181 During the study period there were 53 eligible patients. As 5 refused informed consent and 2 had 182 previously been diagnosed with an invasive mycosis, 46 patients were included. In 16 of these subjects 183 one or more triggers for a diagnostic workup occurred. This resulted in 6 controls and 5 cases, see 184 Table 1 . Principal component analysis of the raw data resulted in 8 principal components (PC's) that 185 described 99.9% of the variance. Of these 1 discriminated between cases and controls. Subsequent 186 canonical discriminant analysis showed a cross validated accuracy value of 90.9% (95% CI 59% to 187 100%). The sensitivity and specificity were 100 (95% CI 48 to 100%) and 83.3% (95% CI 36% to 188 100%). to protocol. Two weeks later however, probable aspergillosis was diagnosed. In retrospect, very small 206 pulmonary lesions were already seen two weeks before at the locations where later aspergilloma 207 developed. Therefore, he was classified as being a case in our study. Out of interest, we also performed 208 a second exhaled breath analysis two weeks later, when we diagnosed probable aspergillosis. This 209 measurement was not used to derive the pattern recognition algorithm for our primary analysis, off 210 course. We compared the two exhaled breath analyses. Although the first signal (discriminant score of -211 0.49) was less pronounced than the second (-1.37), it did already indicate IA. 212 213 To our knowledge, this is the first study examining the accuracy of exhaled air in the early diagnosis of 214 invasive aspergillosis. It is however in line with previous in vitro research, which already showed that 215 an eNose can reliably differentiate in vitro the most frequently encountered pathogens in pneumonia. patients with a high pneumonia score and the 29 patients with a low pneumonia score. Our data thus 225 support and extend the accumulating evidence that eNose technology can be used to diagnose 226 pulmonary infections. 227
228
Our study has a number of strong points. It studied a prospective cohort in which the patients were 229 followed according to a state-of-the-art diagnostic protocol, defining the timing of our exhaled breath 230 analyses and characterizing our population well with respect to whether aspergillosis occurred. This 231 also yielded a well-characterized control group. 232
233
On the other hand, our study is subject to two major limitations. First of all, the sample size was small 234 due to the low incidence of IA. This precluded external validation of our results. As the aim of the 235 study was to detect However, our 100,000 random classifications indicated that the chance of false-236 positive discovery was only 2.2%. It also Eventually, according to guidelines on stepwise assessment of 237 diagnostic accuracy of novel tests, the confirmation of our results in a separate group of subjects that 238 was not involved in generating the pattern-recognition algorithm will be required to definitively 239 establish the ability of an eNose to detect IA. In conclusion, this study shows the potential of eNose technology in the detection of IA in patients 268 experiencing prolonged chemotherapy-induced neutropenia through analysis of exhaled breath. This 269 warrants the next step in testing diagnostic accuracy by performing a large-scale validation study in 270 order to determine how much diagnostic delay can be prevented by adding twice weekly exhaled breath 271 analysis using eNose to a state-of-the-art diagnostic strategy in invasive aspergillosis. (31) 
